Pulmonary arterial hypertension: On the way to a manageable disease

Current Opinion in Investigational Drugs

Volumn 9, Issue 9, 2008, Pages 957-962

  Mucke, H A M ^a  

^a HM Pharma Consultancy   (Austria)

Author keywords

Endothelin receptor antagonist; PDE5 inhibitor; PG analog; Pulmonary hypertension; Soluble guanylate cyclase inhibitor; Vasoactive intestinal peptide

Indexed keywords

2 METHOXYESTRADIOL; AMBRISENTAN; ANTICOAGULANT AGENT; ATACIGUAT; BAY 632521; BERAPROST; BOSENTAN; CALCIUM CHANNEL BLOCKING AGENT; CARELOAD LA; DIGITALIS; DIURETIC AGENT; ENDOTHELIAL NITRIC OXIDE SYNTHASE; ENDOTHELIN RECEPTOR; ENDOTHELIN RECEPTOR ANTAGONIST; GUANYLATE CYCLASE ACTIVATOR; ILOPROST; NITRIC OXIDE; NS 304; NX 1011; PHOSPHODIESTERASE V INHIBITOR; PLACEBO; PROSTACYCLIN; PROSTAGLANDIN; RIOCIGUAT; SILDENAFIL; SITAXSENTAN; TADALAFIL; TERGURIDE; UNCLASSIFIED DRUG; UNINDEXED DRUG; UNIPROST; UT 15C; VASOACTIVE INTESTINAL POLYPEPTIDE; VIVETA;

CELL BASED GENE THERAPY; CLINICAL TRIAL; CONTINUOUS INFUSION; DISEASE CLASSIFICATION; DRUG DELIVERY SYSTEM; DRUG DOSE ESCALATION; DRUG EFFECT; DRUG EFFICACY; DRUG HALF LIFE; ENDOTHELIUM CELL; ENZYME INHIBITION; HUMAN; PULMONARY HYPERTENSION; QUALITY OF LIFE; REVIEW; RISK FACTOR; STEM CELL; SURVIVAL RATE; SURVIVAL TIME; SUSTAINED DRUG RELEASE;

ANIMALS; ANTIHYPERTENSIVE AGENTS; CLINICAL TRIALS AS TOPIC; GENE THERAPY; HUMANS; HYPERTENSION, PULMONARY; NITRIC OXIDE SYNTHASE TYPE III;

EID: 50249097607     PISSN: 14724472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (64)

1. Domenighetti G: Prognosis, screening, early detection and differentiation of arterial pulmonary hypertension. Swiss Med Wkly (2007) 137(23-24):331-336. • A review focusing on the early recognition of PAH that suggests a sequential diagnostic approach.
2. REVEAL (Registry to Evaluate Early and Long Term PAH Disease Management). Actelion Pharmaceuticals Ltd, Allschwil, Switzerland (2008). http://www.revealregistry.com/index.php
3. McGoon MD, Barst RJ, Doyle RL, Liou TG, Miller D: REVEAL registry: Treatment history and treatment at baseline. Chest (2007) 132(Suppl):631S.
4. Rubin LJ, American College of Chest Physicians: Diagnosis and management of pulmonary arterial hypertension: ACCP evidence-based clinical practice guidelines. Chest (2004) 126 (1 Suppl):7S-10S.
5. Galiè N, Rubin LJ, Hoeper MM, Jansa P, Al-Hiti H, Meyer GMB, Chiossi E, Kusic-Pajic A, Simmoneau G: Treatment of patients with mild symptomatic pulmonary arterial hypertension with bosentan (EARLY study): A double-blind, randomised controlled trial. Lancet (2008) 371(9630):2093-2100.
6. Austin ED, Loyd JE: Genetics and mediators in pulmonary arterial hypertension. Clin Chest Med (2007) 28(1):43-57. • A review of genetic associations in FPAH that focuses on the role of bone morphogenetic protein receptor type 2.
7. Sztrymf B, Yaici A, Girerd B, Humbert M: Genes and pulmonary arterial hypertension. Respiration (2007) 74(2):123-132.
8. Taichman DB, Mandel J: Epidemiology of pulmonary arterial hypertension. Clin Chest Med (2007) 28(1):1-22.
9. Bull TM: Screening and therapy of pulmonary hypertension in systemic sclerosis. Curr Opin Rheumatol (2007) 19(6):598-603.
10. Diller GP, Gatzoulis MA: Pulmonary vascular disease in adults with congenital heart disease. Circulation (2007) 115(8):1039-1050.
11. Auger WR, Kim NH, Kerr KM, Test VJ, Fedullo PF: Chronic thromboembolic pulmonary hypertension. Clin Chest Med (2007) 28(1):255-269.
12. Lee MT, Rosenzweig EB, Cairo MS: Pulmonary hypertension in sickle cell disease. Clin Adv Hematol Oncol (2007) 5(8):645-653, 585. • Information on PH in sickle cell disease remains quite limited, although this is a frequent (approximately 30% prevalence) complication in sickle cell disease. This paper presents a good review of the available information.
13. Leslie KO, Trahan S, Gruden J: Pulmonary pathology of the rheumatic diseases. Semin Respir Crit Care Med (2007) 28(4):369-378.
14. Herve P, Le Pavec J, Sztrymf B, Decante B, Savale L, Sitbon O: Pulmonary vascular abnormalities in cirrhosis. Best Pract Res Clin Gastroenterol (2007) 21(1):141-159.
15. Petrosillo N, Chinello P, Vizza D, Cicalini S: Pulmonary hypertension and HIV: Implementation of a regional registry. Infez Med (2005) 13(1):5-15.
16. Souza R, Humbert M, Sztrymf B, Jaïs X, Yaïci A, Le Pavec J, Parent F, Hervé P, Soubrier F, Sitbon O, Simonneau G: Pulmonary arterial hypertension associated with fenfluramine exposure: Report of 109 cases. Eur Respir J (2008) 31(2):343-348. • One of the largest studies of PAH related to the use of anorectics, standardized to the most recent methods and criteria, based on the records of the authors' patients evaluated between 1986 and 2004.
17. Oudiz RJ, Barst RJ, Hansen JE, Sun XG, Garofano R, Wu X, Wasserman K: Cardiopulmonary exercise testing and sixminute walk correlations in pulmonary arterial hypertension. Am J Cardiol (2006) 97(1):123-126.
18. Peacock A, Naeije R, Galié N, Reeves JT: End points in pulmonary arterial hypertension: The way forward. Eur Respir J (2004) 23(6):947-953.
19. Fein SA, Frishman WH: The pathophysiology and management of primary pulmonary hypertension. Cardiol Clin (1987) 5(4):563-576.
20. Cremona G, Higenbottam T: Role of prostacyclin in the treatment of primary pulmonary hypertension. Am J Cardiol (1995) 75(3):67A-71A.
21. Chattaraj SC: Treprostinil sodium Pharmacia. Curr Opin Investig Drugs (2002) 3(4):582-586.
22. Baker SE, Hockman RH: Inhaled iloprost in pulmonary arterial hypertension. Ann Pharmacother (2005) 39(7-8):1265-1274.
23. Bloch KD, Ichinose F, Roberts JD Jr, Zapol WM: Inhaled NO as a therapeutic agent. Cardiovasc Res (2007) 75(2):339-348. • One of the most comprehensive reviews on the distinct niche role of nitric oxide in PAH therapy.
24. Oldfield V, Lyseng-Williamson KA: Bosentan: A review of its use in pulmonary arterial hypertension and systemic sclerosis. Am J Cardiovasc Drugs (2006) 6(3):189-208.
25. Wittbrodt ET, Abubakar A: Sitaxsentan for treatment of pulmonary hypertension. Ann Pharmacother (2007) 41(1):100-105.
26. Barst RJ: A review of pulmonary arterial hypertension: Role of ambrisentan. Vasc Health Risk Manag (2007) 3(1):11-22.
27. Barnett CF, Machada RF: Sildenafil in the treatment of pulmonary hypertension. Vasc Health Risk Manag (2006) 2(4):411-422.
28. Melian EB, Goa KL: Beraprost: A review of its pharmacology and therapeutic efficacy in the treatment of peripheral arterial disease and pulmonary arterial hypertension. Drugs (2002) 62(1):107-133.
29. Toray Industries Inc: Announcement of the launch of the pulmonary arterial hypertension agent Careload LA tablets 60μg in Japan. Press Release (2007): December 19.
30. United Therapeutics Corp: Triumph -1 trial of Viveta in pulmonary arterial hypertension meets primary endpoint. Press Release (2007): November 01.
31. United Therapeutics Corp: New Drug Application for inhaled treprostinil submitted to the U.S. Food and Drug Administration. Press Release (2008): June 30.
32. United Therapeutics Corp: United Therapeutics Corp. JP Morgan Ann Healthcare Conf (2008): January 07.
33. Channick RN, Olschewski H, Seeger W, Staub T, Voswinckel, Rubin LJ: Safety and efficacy of inhaled treprostinil as add-on therapy to bosentan in pulmonary arterial hypertension. J Am Coll Cardiol (2006) 48(7):1433-1437.
34. Voswinckel R, Enke B, Reichenberger F, Kohstall M, Kreckel A, Krick S, Gall H, Gessler T, Schmehl T, Ghofrani HA, Schermuly RT et al: Favorable effects of inhaled treprostinil in severe pulmonary hypertension: Results from randomized controlled pilot studies. J Am Coll Cardiol (2006) 48(8):1672-1681.
35. NCT00325442: FREEDOM-C: Oral treprostinil in combination with an endothelin receptor antagonist (ERA) and/or a phosphodiesterase-5 (PDE-5) inhibitor for the treatment of pulmonary arterial hypertension (PAH). NIH, Bethesda, MD, USA (2008). http://www.clinicaltrial.gov/ct2/show/NCT00325442? term=NCT00325442&rank=1
36. NCT00325403: FREEDOM-M: Oral treprostinil as monotherapy for the treatment of pulmonary arterial hypertension (PAH). NIH, Bethesda, MD, USA (2008). http://www.clinicaltrial.gov/ct2/show/NCT00325403?term= NCT00325403&rank=1
37. Palmieri EA, Affuso F, Fazio S, Lembo D: Tadalafil in primary pulmonary arterial hypertension. Ann Intern Med (2004) 141(9):743-744.
38. Affuso F, Palmieri EA, Di Conza P, Guardasole V, Fazio S: Tadalafil improves quality of life and exercise tolerance in idiopathic pulmonary arterial hypertension. Int J Cardiol (2006) 108(3):429-431.
39. NCT00125918: PHIRST-1: Tadalafil in the treatment of pulmonary arterial hypertension. NIH, Bethesda, MD, USA (2008). http://www. clinicaltrial.gov/ct2/show/NCT00125918?term=tadalafil&rank=3
40. Eli Lilly Japan KK: Eli Lilly Japan's new drugs in the R&D pipeline. Pharma Jpn (2007): March 30.
41. Eli Lilly & Co: Lilly showcases pipeline opportunities to Wall Street, sets 2008 financial guidance and outlines transformation strategy. Press Release (2007): December 06.
42. Haberl I, Frei K, Ramsebner R, Doberer D, Petkov V, Albinni S, Lang I, Lucas T, Mosgoeller W: Vasoactive intestinal peptide gene alterations in patients with idiopathic pulmonary arterial hypertension. Eur J Hum Genet (2007) 15(1):18-22. • Point mutations in the VIP gene that were detected in patients (n = 8) with IPAH were characterized.
43. Petkov V, Mosgoeller W, Ziesche R, Raderer M, Stiebellehner L, Vonbank K, Funk GC, Hamilton G, Novotny C, Burian B, Block LH: Vasoactive intestinal peptide as a new drug for treatment of primary pulmonary hypertension. J Clin Invest (2003) 111(9):1339-1346.
44. Product pipeline. Biogen Idec Inc, Basel, Switzerland (2008). http://www.biogenidec.com/site/pipeline.html
45. Evgenov OV, Ichinose F, Evgenov NV, Gnoth MJ, Falkowski GE, Chang Y, Bloch KD, Zapol WM: Soluble guanylate cyclase activator reverses acute pulmonary hypertension and augments the pulmonary vasodilator response to inhaled nitric oxide in awake lambs. Circulation (2004) 110(15):2253-2259.
46. NCT00454558: An open multiple dose titration study in patients with pulmonary hypertension. NIH, Bethesda, MD, USA (2008). http://www. clinicaltrial.gov/ct2/show/NCT00454558?term=nct00454558&rank=1
47. Bayer AG: Fact sheet: sGC stimulator. Company Publication (2007): June 19. http://www.bayerhealthcare.com/html/pdf/sGCStim_190607_EN. pdf
48. sanofi-aventis: Research and development meeting. Company Presentation (2007): September 17.
49. Hauso O, Gustafsson BI, Loennechen JP, Stunes AK, Nordrum I, Waldum HL: Long-term serotonin effects in the rat are prevented by terguride. Regul Pept (2007) 143(1-3):39-46. • This paper describes the results from the only developmentally advanced therapeutic approach, which has resulted from the serotonin hypothesis of hypoxic pulmonary vascular remodeling.
50. ErgoNex Pharma GmbH: Ergonex Pharma initiates phase II clinical trial of terguride in pulmonary arterial hypertension. Press Release (2008): January 29.
51. Kuwano K, Hashino A, Asaki T, Hamamoto T, Yamada T, Okubo K, Kuwabara K: 2-[4-[(5,6-diphenylpyrazin-2-yl)(isopropyl)amino]-butoxy]-N- (methylsulfonyl)acetamide (NS-304), an orally available and long-acting prostacyclin receptor agonist prodrug. J Pharmacol Exp Ther (2007) 322(3):1181-1188.
52. PGI2 receptor agonist. Actelion Ltd, Allschwil, Switzerland (2008). http://www.actelion.com/uninet/www/www_main_p.nsf/Content/ PGI2+Receptor+Agonist
53. NCT00323024: Dose determination safety and activity study of inhaled NX1011 to treat pulmonary arterial hypertension. NIH, Bethesda, MD, USA (2007). http://www.clinicaltrials.gov/ct2/show/NCT00323024?term= NCT00323024&rank=1
54. Moya MP, Gow AJ, Califf RM, Goldberg RN, Stamler JA: Inhaled ethyl nitrite gas for persistent pulmonary hypertension of the newborn. Lancet (2002) 360(9327):141-143.
55. Zhao YD, Courtman DW, Deng Y, Kugathasan L, Zhang Q, Stewart DJ: Rescue of monocrotaline-induced pulmonary arterial hypertension using bone marrow-derived endothelial-like progenitor cells: Efficacy of combined cell and eNOS gene therapy in established disease. Circ Res (2005) 96(4):442-450.
56. United Therapeutics Corp: United Therapeutics affiliate initiates first-ever gene-therapy trial for pulmonary arterial hypertension. Press Release (2006): December 12.
57. Northern Therapeutics Inc: Northern Therapeutics and MaxCyte initiate landmark engineered cell therapy trial for fatal lung disease. Press Release (2006): December 12.
58. Tofovic SP, Zhang X, Jackson EK, Dacic S, Petrusevska G: 2-Methoxyestradiol mediates the protective effects of estradiol in monocrotaline-induced pulmonary hypertension. Vascul Pharmacol (2006) 45(6):358-367.
59. PR Pharmaceuticals Inc: PRP announces initiation of a phase I study of a new potential treatment for pulmonary arterial hypertension. Press Release (2006): March 27.
60. PR Pharmaceuticals Inc: PR Pharmaceuticals' PulmoLAR granted Orphan Drug Status. Press Release (2005): May 12.
61. PR Pharmaceuticals Inc: New patent issued to the University of Pittsburgh for 2-methoxyestradiol. Press Release (2006): March 16.
62. Snow JL, Kawut SM: Surrogate end points in pulmonary arterial hypertension: Assessing the response to therapy. Clin Chest Med (2007) 28(1):75-89.
63. BAYER HEALTHCARE AG (Krahn T, Stasch J-P, Weimann G, Thielemann W): Use of soluble guanylate cyclase activators for treating acute and chronic lung diseases. WO-2007039155 (2007).
64. UNIVERSITY OF PITTSBURGH (Tofovic SP, Jackson EK): Estradiol metabolites for the treatment of pulmonary hypertension. WO-2004073643 (2004).